Emergent BioSolutions Inc. (NYSE:EBS) Position Trimmed by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lowered its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 42.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,290,230 shares of the biopharmaceutical company’s stock after selling 934,497 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Emergent BioSolutions were worth $12,335,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. SBI Securities Co. Ltd. bought a new position in Emergent BioSolutions in the 4th quarter valued at about $63,000. Stifel Financial Corp acquired a new stake in Emergent BioSolutions in the 3rd quarter valued at about $96,000. FORA Capital LLC acquired a new stake in Emergent BioSolutions in the 3rd quarter valued at about $103,000. Landscape Capital Management L.L.C. acquired a new stake in Emergent BioSolutions in the 3rd quarter valued at about $141,000. Finally, Hussman Strategic Advisors Inc. acquired a new stake in Emergent BioSolutions in the 4th quarter valued at about $201,000. Institutional investors own 78.40% of the company’s stock.

Insider Buying and Selling at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the sale, the director now directly owns 101,100 shares in the company, valued at $589,413. This trade represents a 25.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.20% of the company’s stock.

Emergent BioSolutions Trading Down 0.6 %

Shares of EBS stock opened at $5.70 on Friday. Emergent BioSolutions Inc. has a 12 month low of $1.82 and a 12 month high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The company has a market cap of $309.45 million, a PE ratio of -1.39 and a beta of 1.80. The business’s 50 day moving average is $8.48 and its two-hundred day moving average is $8.71.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million during the quarter, compared to analysts’ expectations of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the prior year, the business earned ($0.77) earnings per share. Equities analysts predict that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Analysts Set New Price Targets

EBS has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Friday. StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.